Biocryst Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOCRYST
BIOCRYST has three approved drugs.
There are eighteen US patents protecting BIOCRYST drugs.
Summary for Biocryst
| US Patents: | 18 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-002 | Dec 11, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-002 | Dec 3, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-004 | Dec 11, 2025 | RX | Yes | Yes | 12,552,750*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-001 | Dec 3, 2020 | RX | Yes | No | 12,545,646*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,503,745 | ⤷ Start Trial |
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,562,861 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Biocryst Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Malaysia | 199131 | ⤷ Start Trial |
| South Africa | 201606320 | ⤷ Start Trial |
| Colombia | 2021007172 | ⤷ Start Trial |
| Spain | 2836373 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biocryst Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3113772 | C202130056 | Spain | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1544; DATE OF AUTHORISATION: 20210430; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1544; DATE OF FIRST AUTHORISATION IN EEA: 20210430 |
| 3113772 | CR 2021 00040 | Denmark | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/21/1544 20210504 |
| 3113772 | 2190040-2 | Sweden | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/21/1544, 2021-05-04; PRV HAR FATTAT BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 2290042-7 2290031-0 1590027-7 1590062-4 2190040-2 2290010-4 1990014-1 2190030-3 1590011-1 1490013-8 1490014-6 1490015-3 1890033-2 1990042-2 1990055-4 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. DEN BESLUTADE SKYDDSTIDEN FRAMGAR AV SVENSK PATENTDATABAS. |
| 3113772 | CA 2021 00040 | Denmark | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/21/1544 20210504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
